Arcalyst 200 MG
Ended Awarded
- Contract number
- 36C24526N0294
- Awardee
-
Kiniksa Pharmaceuticals (Uk), LTD. UEI HBHWNLNMHSV5
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $34,023
Award facts
- Contract value 100% obligated
- $34,022.62 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Great Britain, United Kingdom
Award details come from SAM.gov/FPDS.
About this award
The Department of Veterans Affairs Veterans Integrated Service Network 5 awarded a $34,022.62 firm fixed-price delivery order to Kinikska Pharmaceuticals (UK), LTD. for the supply of Arcalyst 200 mg on January 31, 2026, with an ultimate completion date of February 4, 2026. This delivery order was issued under the General Services Administration's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and carries no set-aside designation, indicating open competition procurement. The award funds the supply of Arcalyst (Rilonacept), an injectable pharmaceutical indicated for treating chronic inflammatory disorders including recurrent pericarditis and cryopyrin-associated periodic syndromes, with performance to occur in Great Britain, United Kingdom.
Kinikska Pharmaceuticals (UK), LTD., a foreign-owned biopharmaceutical company headquartered in London, has established itself as a primary federal supplier of this specialized therapeutic agent through multiple indefinite delivery vehicles, including a $5.9 million Blanket Purchase Agreement with the VA National Acquisition Center and a $700,000 multiple-award Federal Supply Schedule contract with Veterans Integrated Service Network 12. The company has consistently delivered pharmaceutical products to support VA healthcare operations and federal medical centers since October 2021, with collective obligations exceeding $1.7 million across its federal contract portfolio. This delivery order represents continued pharmaceutical procurement under the established contractual framework supporting veteran healthcare delivery across multiple service networks.
Quick answers
Who was awarded contract 36C24526N0294?
36C24526N0294 was awarded to Kiniksa Pharmaceuticals (Uk), LTD. by Veterans Integrated Service Network 5 (Veterans Health Administration) on January 31, 2026.
How much is contract 36C24526N0294 worth?
The government has obligated $34,023 on 36C24526N0294.
Is contract 36C24526N0294 an order under another contract?
Yes. 36C24526N0294 is a delivery order under 36F79722D0002, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0294 competed?
The extent of competition for 36C24526N0294 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award